NCT05043961

Brief Summary

The sacro-iliac joint is a large joint that can be the source of chronic pain. Many treatment options have been proposed to treat SIJ pain, with variable efficacy. The next step in managing those patients who can't get sustained pain relief from conservative treatment is radiofrequency ablation (RFA) of the SIJ's posterior innervation. However, the success rate of SIJ RFA, as determined by the proportion of patients reporting greater than 50% pain relief 6 months after the intervention, varies substantially across studies, ranging from 38-71 %. This may be explained partly by the fact that there may be incomplete lesioning of the target nerves supplying the joint. To overcome these particularities, two RFA techniques have emerged: cooled RFA and bipolar RFA. Cooled radiofrequency is the one that has been studied the most, and good evidence supports its efficacy. However, its superiority to conventional RF for the treatment of SIJ pain is not confirmed. Alternatively, a bipolar RFA technique using conventional radiofrequency needles and equipment can be used. The efficacy of this relatively newer technique has been demonstrated by only one study, and although the results were promising, it is not known whether they could be replicated. The success of the palisade technique could be enhanced by using multi-tined expandable electrodes, such as the 3-tined Trident cannulas, with only small increases in cost. In clinical practice, the palisade technique using 3-tines needles is routinely used. However, its efficacy has not been formally evaluated. The primary objective of this prospective cohort study will be to determine the success rate of the palisade SIJ RFA (P-RF) technique using the 3-tined needles, determined as the proportion of patients reporting \>50% pain relief, 6 months after the procedure.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 2, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 14, 2021

Completed
9 months until next milestone

Study Start

First participant enrolled

June 1, 2022

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 11, 2025

Completed
Last Updated

February 13, 2025

Status Verified

February 1, 2025

Enrollment Period

2.5 years

First QC Date

September 2, 2021

Last Update Submit

February 11, 2025

Conditions

Keywords

radiofrequency ablationSacroiliac joint painchronic pain

Outcome Measures

Primary Outcomes (1)

  • Success rate

    proportion of patients reporting \>50% pain relief

    6 months

Secondary Outcomes (16)

  • Succes rate

    3 months

  • Succes rate

    1 month

  • Succes rate

    10 month

  • Change in Pain score

    1 month

  • Change in Pain score

    3 month

  • +11 more secondary outcomes

Other Outcomes (4)

  • analgesia from sacral lateral branch block

    baseline

  • Success rate

    3 months

  • Success rate

    6 months

  • +1 more other outcomes

Study Arms (1)

study group

Patients who report \>50% pain relief after an intra articular sacroiliac joint injection but lasting less than 3 months who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic and who meet inclusion criteria will be offered to participate in this study. Intervention: Sacroiliac joint rafiofrequency ablation using the bipolar palissade approach and 3-tined needles

Procedure: Palisade sacroiliac joint radiofrequency ablation using 3-tined needles

Interventions

Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output. The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned. Lesioning the L5 dorsal ramus: o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion.

study group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who are candidates for sacroiliac joint radio frequency ablation at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic

You may qualify if:

  • years and older
  • Low back pain caused by SIJ dysfunction lasting \> 6 months:
  • Predominantly axial pain below the L5 vertebrae with an average daily Verbal Numercial Scale Score (VNS) \>4;
  • \>50% pain relief after a fluoroscopically guided intraarticular injection of local anesthetic and steroids in the SIJ but lasting less than 3 months. Injection performed in the last 6 months prior to enrollment.

You may not qualify if:

  • Pregnancy
  • Spinal pathology that may impede recovery such as severe spondylolisthesis at L5/S1, severe scoliosis, or lumbar fusion;
  • Active radicular pain;
  • Worker's compensation;
  • Cognitive limitation or linguistic barrier making pain assessment through questionnaire impossible;
  • Implanted pacemaker or defibrillator;
  • Refusal.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maisonneuve-Rosemont Hospital

Montreal, Quebec, H1T2M4, Canada

Location

MeSH Terms

Conditions

Back PainChronic Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 2, 2021

First Posted

September 14, 2021

Study Start

June 1, 2022

Primary Completion

December 1, 2024

Study Completion

February 11, 2025

Last Updated

February 13, 2025

Record last verified: 2025-02

Locations